Company Profile
Innate Pharma Stock Price, News & Catalysts
- Ticker:
- IPHA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France
Stock performance
2.26 USD (+8.13%)
Close
Last updated: August 21, 2026
171M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, IPHA closed up 8.13% at $2.26. No new same-company headline was identified in the current news window.
Company overview
Innate Immunity Oncology Company
Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer.
Lacutamab
Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma.
ADC and Partnered Pipeline
IPH4502 is a Nectin-4 ADC, while partnered programs include monalizumab and anti-CD39 antibody IPH5201 with AstraZeneca.
Future catalysts
- Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
- Phase 3 PACIFIC-9 data for the monalizumab-containing regimen are planned for the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Innate Pharma (IPHA)?
Innate Pharma (IPHA) most recently closed at 2.26 USD, a +8.13% move versus the previous session.
What is the market cap of Innate Pharma (IPHA)?
Innate Pharma currently has a market capitalization of 171M USD on BioPharmSignal.
What does Innate Pharma do?
Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include monalizumab and anti-CD39...
On which exchange is IPHA stock listed?
Innate Pharma (IPHA) is associated with NASDAQ, France, Biopharma.
What is TELLOMAK-3?
Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
Which conditions is Innate Pharma targeting with TELLOMAK-3?
Innate Pharma is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Innate Pharma describe recent progress with TELLOMAK-3?
Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
What is PACIFIC-9?
Phase 3 PACIFIC-9 data for the monalizumab-containing regimen are planned for the second half of 2026.